A Discrete Gene Signature Is a Diagnostic and Predictive Biomarker for Kidney Transplant Rejection
|
By LabMedica International staff writers Posted on 15 Jul 2013 |
|
A genetic signature comprising two messenger RNA molecules that encode immune system proteins and one noncoding RNA molecule that participates in protein production has been shown to be diagnostic and prognostic of acute cellular rejection in kidney transplants.
The standard test for the diagnosis of acute rejection in kidney transplants is the renal biopsy. However, biopsy samples, in addition to being invasive with risk of infection, may not give the physician an accurate impression of the overall state of the kidney, since biopsy specimens are small and may not contain any injured tissue.
Investigators at the [US] National Institutes of Health (Bethesda, MD, USA) and colleagues at Weill Cornell Medical College (New York, NY, USA) and the University of Pennsylvania (Philadelphia, USA) sought a noninvasive test that would accurately detect or predict kidney transplant rejection.
To this end, they collected 4,300 urine specimens from 485 kidney-graft recipients from day three through month 12 after transplantation. Messenger RNA (mRNA) levels were measured in urinary cells taken from the samples and correlated with allograft-rejection status with the use of logistic regression.
The investigators found that a three-gene signature representing 18S ribosomal RNA (rRNA), CD3epsilon mRNA, and interferon-inducible protein 10 (IP-10) mRNA discriminated between biopsy specimens showing acute cellular rejection and those not showing rejection. The signature distinguished acute cellular rejection from acute antibody-mediated rejection and borderline rejection. It also distinguished patients who received anti-interleukin-2 receptor antibodies from those who received T-cell-depleting antibodies and was diagnostic of acute cellular rejection in both groups. Urinary tract infection did not affect the signature.
Levels of the signature RNAs in repeated urine samples remained below the diagnostic threshold for acute cellular rejection in the group of patients with no rejection, but in the group with rejection, there was a sharp rise during the weeks before a biopsy revealed signs of rejection.
"The test described in this study may lead to better, more personalized care for kidney transplant recipients by reducing the need for biopsies and enabling physicians to tailor immunosuppressive therapy to individual patients," said contributing author Dr. Nancy Bridges, transplantation branch chief at the [US] National Institutes of Health. "The National Institutes of Health-funded Clinical Trials in Organ Transplantation (CTOT) cooperative research consortium provided the infrastructure and collaborative environment needed to conduct the large, rigorous, multicenter study that established the efficacy of this biomarker-based test."
The study was published in the July 4, 2013, issue of the New England Journal of Medicine.
Related Links:
National Institutes of Health
Weill Cornell Medical College
University of Pennsylvania
The standard test for the diagnosis of acute rejection in kidney transplants is the renal biopsy. However, biopsy samples, in addition to being invasive with risk of infection, may not give the physician an accurate impression of the overall state of the kidney, since biopsy specimens are small and may not contain any injured tissue.
Investigators at the [US] National Institutes of Health (Bethesda, MD, USA) and colleagues at Weill Cornell Medical College (New York, NY, USA) and the University of Pennsylvania (Philadelphia, USA) sought a noninvasive test that would accurately detect or predict kidney transplant rejection.
To this end, they collected 4,300 urine specimens from 485 kidney-graft recipients from day three through month 12 after transplantation. Messenger RNA (mRNA) levels were measured in urinary cells taken from the samples and correlated with allograft-rejection status with the use of logistic regression.
The investigators found that a three-gene signature representing 18S ribosomal RNA (rRNA), CD3epsilon mRNA, and interferon-inducible protein 10 (IP-10) mRNA discriminated between biopsy specimens showing acute cellular rejection and those not showing rejection. The signature distinguished acute cellular rejection from acute antibody-mediated rejection and borderline rejection. It also distinguished patients who received anti-interleukin-2 receptor antibodies from those who received T-cell-depleting antibodies and was diagnostic of acute cellular rejection in both groups. Urinary tract infection did not affect the signature.
Levels of the signature RNAs in repeated urine samples remained below the diagnostic threshold for acute cellular rejection in the group of patients with no rejection, but in the group with rejection, there was a sharp rise during the weeks before a biopsy revealed signs of rejection.
"The test described in this study may lead to better, more personalized care for kidney transplant recipients by reducing the need for biopsies and enabling physicians to tailor immunosuppressive therapy to individual patients," said contributing author Dr. Nancy Bridges, transplantation branch chief at the [US] National Institutes of Health. "The National Institutes of Health-funded Clinical Trials in Organ Transplantation (CTOT) cooperative research consortium provided the infrastructure and collaborative environment needed to conduct the large, rigorous, multicenter study that established the efficacy of this biomarker-based test."
The study was published in the July 4, 2013, issue of the New England Journal of Medicine.
Related Links:
National Institutes of Health
Weill Cornell Medical College
University of Pennsylvania
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
H.pylori Test
Humasis H.pylori Card
New
Myeloperoxidase Assay
IDK MPO ELISA
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
Novel Point-of-Care Technology Delivers Accurate HIV Results in Minutes
HIV diagnostic methods have traditionally relied on detecting HIV-specific antibodies, which typically appear weeks after infection. This delayed detection has hindered early diagnosis, complicating patient... Read more
Blood Test Rules Out Future Dementia Risk
Previous studies have suggested that specific biomarkers, such as tau217, Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP), may be valuable for early dementia diagnosis.... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Microbiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Pathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
New Collaboration to Advance Microbial Identification for Infectious Disease Diagnostics
With the rise of global pandemics, antimicrobial resistance, and emerging pathogens, healthcare systems worldwide are increasingly dependent on advanced diagnostic tools to guide clinical decisions.... Read more
